Stay updated on Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe study status was updated to Completed with actual completion dates, replacing the previous 'Active, not recruiting' status. The page revision was updated to v3.4.2 and the funding-status notice was removed.SummaryDifference0.8%

- Check17 days agoChange DetectedA government funding status notice banner was added and the site revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check24 days agoChange DetectedGlossary toggle added; a new label 'Last Update Submitted that Met QC Criteria' appears and a 'No FEAR Act Data' notice is shown. The site revision is updated from v3.3.4 to v3.4.0.SummaryDifference0.2%

- Check38 days agoChange DetectedAdded Revision: v3.3.4 and removed Revision: v3.3.3. This is a minor metadata update with no impact on study details or user-facing content.SummaryDifference0.1%

- Check60 days agoChange DetectedAdded a dedicated Locations section with California (Los Angeles) at Cedars-Sinai Medical Center and updated the page revision to v3.3.3. The older California Locations entry, HHS Vulnerability Disclosure, and the prior v3.3.2 reference were removed.SummaryDifference0.2%

- Check74 days agoChange DetectedThe Study Record Dates now shows 'Last Update Posted (Estimated)' with new dates (2025-11-14, 2025-12-02). The previous generic 'Last Update Posted' label was removed.SummaryDifference0.3%

Stay in the know with updates to Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page.